BioVaxys Extends Deadline for Private Placement Offering Amid Investor Interest

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //

VANCOUVER, BC, Feb. 7, 2025 /CNW/ — BioVaxys Technology Corp. BIOV 5LB (“BioVaxys” or the “Company“) is announcing an extension of its non-brokered private placement offering. This follows earlier announcements made on January 10, 2025, and January 23, 2025. The offering involves units priced at $0.05 per Unit (the “Private Placement“). Each Unit contains one (1) common share and one (1) whole Share purchase warrant. Each Warrant can be converted into one additional Share at an exercise price of $0.15 within 24 months from issuance.

To allow more investors to participate, the Company has moved the closing date for the fourth and final tranche (the “Final Tranche“) from February 7, 2025 to on or before February 14, 2025. The funds raised will primarily support working capital. Investors should note that all newly issued securities will be subject to a four-month hold period as outlined by applicable securities laws.

This announcement does not represent an offer or solicitation to buy securities in the United States. The securities mentioned have not been registered under the United States Securities Act of 1933 and cannot be sold in the U.S. without meeting registration requirements or qualifying for exemptions.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), based in British Columbia, Canada, focuses on clinical-stage biopharmaceuticals aimed at improving patient outcomes. The Company uses the DPX™ immune-educating technology platform and its HapTenix© ‘neoantigen’ tumor cell construct platform to target cancers, infectious diseases, and more. The innovative DPX™ platform is designed to deliver antigens effectively to stimulate lasting immune responses, demonstrated through various studies. BioVaxys’ common shares trade on the Canadian Securities Exchange under the ticker “BIOV,” on the Frankfurt Bourse as 5LB, and are also quoted in the U.S. on OTC Markets. For more information, visit www.biovaxys.com and follow us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 740 358 0555

Cautionary Statements Regarding Forward Looking Information

This news release contains “forward-looking information” and “forward-looking statements” as defined by applicable securities legislation. Statements beyond historical facts, including those related to the Private Placement, are considered forward-looking. Such statements often include terms like “expects,” “anticipates,” “believes,” “intends,” and others indicating potential future outcomes. There is no guarantee these predictions will be accurate as actual results might differ significantly due to various unpredictable factors.

These forward-looking statements are based on assumptions that BioVaxys successfully develops and tests its vaccines. However, uncertainties related to business, economy, and competition could alter actual outcomes compared to what is projected. Many variables can affect performance, and the Company does not commit to updating these statements unless required by law.

The Canadian Securities Exchange has neither reviewed nor approved this press release and does not bear any responsibility for its content.

Logo – https://mma.prnewswire.com/media/2415135/5157861/BioVaxys_Technology_Corp_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/biovaxys-announces-extension-of-private-placement-closing-date-302371688.html

SOURCE BioVaxys Technology Corp.

View original content: http://www.newswire.ca/en/releases/archive/February2025/07/c2366.html